Danaher Co. (NYSE:DHR) to Post Q1 2024 Earnings of $1.72 Per Share, Zacks Research Forecasts

Danaher Co. (NYSE:DHR) – Research analysts at Zacks Research cut their Q1 2024 earnings per share estimates for Danaher in a research note issued on Wednesday, April 17th. Zacks Research analyst R. Department now anticipates that the conglomerate will post earnings per share of $1.72 for the quarter, down from their previous estimate of $1.74. The consensus estimate for Danaher’s current full-year earnings is $7.62 per share. Zacks Research also issued estimates for Danaher’s Q2 2024 earnings at $1.62 EPS, Q3 2024 earnings at $1.90 EPS, Q4 2024 earnings at $2.34 EPS, Q3 2025 earnings at $2.14 EPS, Q4 2025 earnings at $2.42 EPS, FY2025 earnings at $8.47 EPS, Q1 2026 earnings at $2.25 EPS and FY2026 earnings at $10.01 EPS.

A number of other analysts have also issued reports on DHR. KeyCorp lifted their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. JPMorgan Chase & Co. boosted their price objective on Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Royal Bank of Canada boosted their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Finally, Barclays boosted their price objective on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 10th. Six analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $268.27.

Danaher Stock Performance

Shares of NYSE:DHR opened at $239.39 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The business’s 50 day moving average price is $249.28 and its 200-day moving average price is $229.86. The firm has a market capitalization of $177.28 billion, a PE ratio of 37.46, a P/E/G ratio of 3.64 and a beta of 0.83. Danaher has a 1 year low of $182.09 and a 1 year high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. The firm had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business’s revenue was down 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.87 earnings per share.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a $0.27 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is currently 16.90%.

Insider Buying and Selling at Danaher

In related news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Walter G. Lohr sold 3,289 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the completion of the sale, the director now owns 14,129 shares in the company, valued at approximately $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock worth $8,265,802 over the last quarter. 10.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently modified their holdings of the company. Moneta Group Investment Advisors LLC grew its stake in Danaher by 96,490.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock worth $6,180,839,000 after purchasing an additional 23,262,904 shares in the last quarter. Norges Bank acquired a new position in Danaher during the 4th quarter worth $2,057,164,000. Wellington Management Group LLP grew its stake in Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after purchasing an additional 3,905,449 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in Danaher by 214.4% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after purchasing an additional 2,096,038 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.